Identification and characterization of a small-molecule inhibitor of Wnt signaling in glioblastoma cells

Molecular Cancer Therapeutics

Volumn 12, Issue 7, 2013, Pages 1180-1189

  De Robertis, Alessandra ^a   Valensin, Silvia ^a   Rossi, Marco ^a   Tunici, Patrizia ^a   Verani, Margherita ^a   De Rosa, Antonella ^a   Giordano, Cinzia ^a   Varrone, Maurizio ^a   Nencini, Arianna ^a   Pratelli, Carmela ^a   Benicchi, Tiziana ^a   Bakker, Annette ^a,d   Hill, Jeffrey ^b   Sangthongpitag, Kanda ^b   Pendharkar, Vishal ^b   Liu, Boping ^b   Ng, Fui Mee ^b   Then, Siew Wen ^b   Tai, Shi Jing ^b   Cheong, Seong Moon ^c   He, Xi ^c   Caricasole, Andrea ^a   Salerno, Massimiliano ^a   more..

^a SienaBiotech   (Italy)

^b Agency for Science   (Singapore)

^c HARVARD MEDICAL SCHOOL   (United States)

^d Children's Tumor Foundation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APC PROTEIN; AXIN; BETA CATENIN; IWR 2; PROTEIN INHIBITOR; SEN 461; SEN 973; UNCLASSIFIED DRUG; WNT PROTEIN; XAV 939;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG SCREENING; DRUG TARGETING; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN CELL; MOLECULAR LIBRARY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; TUMOR XENOGRAFT; WNT SIGNALING PATHWAY; XENOPUS;

EID: 84880070384     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-12-1176-T     Document Type: Article

References (41)

1. Nusse R, Varmus HE. Wnt genes. Cell 1992;69:1073-87.
2. Nusse R. Wnt signaling in disease and in development. Cell Res 2005;15:28-32. (Pubitemid 41653961)
3. MacDonald BT, Tamai K, He X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell 2009;17:9-26.
4. Barker N, Clevers H. Mining the Wnt pathway for cancer therapeutics. Nat Rev Drug Discov 2006;5:997-1014. (Pubitemid 44835127)
5. Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B, et al. Activation of beta-catenin -Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 1997;275:1787-90. (Pubitemid 27136715)
6. Satoh S, Daigo Y, Furukawa Y, Kato T, Miwa N, Nishiwaki T, et al. AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nat Genet 2000;24:245-50. (Pubitemid 30132191)
7. Benhaj K, Akcali KC, Ozturk M. Redundant expression of canonical Wnt ligands in human breast cancer cell lines. Oncol Rep 2006;15:701-7.
8. Yang L, Wu X, Wang Y, Zhang K, Wu J, Yuan YC, et al. Fzd7 has a critical role in cell proliferation in triple negative breast cancer. Oncogene 2011;30:4437-46.
9. Uematsu K, He B, You L, Xu Z, McCormick F, Jablons DM. Activation of the Wnt pathway in non small cell lung cancer: evidence of dishevelled overexpression. Oncogene 2003;22:7218-21. (Pubitemid 37378553)
10. Bafico A, Liu G, Goldin L, Harris V, Aaronson SA. An autocrine mechanism for constitutive Wnt pathway activation in human cancer cells. Cancer Cell 2004;6:497-506. (Pubitemid 39469985)
11. Rajan N, Burn J, Langtry J, Sieber-Blum M, Lord CJ, Ashworth A. Transition from cylindroma to spiradenoma in CYLD-defective tumours is associated with reduced DKK2 expression. J Pathol 2011;224:309-21.
12. Zheng H, Ying H, Wiedemeyer R, Yan H, Quayle SN, Ivanova EV, et al. PLAGL2 regulates Wnt signaling to impede differentiation in neural stem cells and gliomas. Cancer Cell 2010;17:497-509.
13. Zhang N, Wei P, Gong A, Chiu WT, Lee HT, Colman H, et al. FoxM1 promotes β-catenin nuclear localization and controls Wnt target-gene expression and glioma tumorigenesis. Cancer Cell 2011;20:427-42.
14. Augustin I, Goidts V, Bongers A, Kerr G, Vollert G, Radlwimmer B, et al. The Wnt secretion protein Evi/Gpr177 promotes glioma tumourigenesis. EMBO Mol Med 2011;4:38-51.
15. Pu P, Zhang Z, Kang C, Jiang R, Jia Z, Wang G, et al. Downregulation of Wnt2 and beta-catenin by siRNA suppresses malignant glioma cell growth. Cancer Gene Ther 2009;16:351-61.
16. Pulvirenti T, Van Der Heijden M, Droms LA, Huse JT, Tabar V, Hall A. Dishevelled 2 signaling promotes self-renewal and tumorigenicity in human gliomas. Cancer Res 2011;71:7280-90.
17. Lambiv WL, Vassallo I, Delorenzi M, Shay T, Diserens AC, Misra A, et al. The Wnt inhibitory factor 1 (WIF1) is targeted in glioblastoma and has a tumor suppressing function potentially by induction of senescence. Neuro Oncol 2011;13:736-47.
18. Jin X, Jeon HY, Joo KM, Kim JK, Jin J, Kim SH, et al. Frizzled 4 regulates stemness and invasiveness of migrating glioma cells established by serial intracranial transplantation. Cancer Res 2011;71:3066-75.
19. Semënov MV, Tamai K, Brott BK, Kühl M, Sokol S, He X. Head inducer Dickkopf-1 is a ligand for Wnt coreceptor LRP6. Curr Biol 2001;11:951-61.
20. Kruse CA, Mitchell DH, Kleinschmidt-DeMasters BK, Franklin WA, Morse HG, Spector EB, et al. Characterization of a continuous human glioma cell line DBTRG-05MG: growth kinetics, karyotype, receptor expression, and tumor suppressor gene analyses. In Vivo Cell Dev Biol 1992;28A:609-14. (Pubitemid 23297274)
21. Clevers H. Wnt beta-catenin/signaling in development and disease. Cell 2006;127:469-80.
22. Moon RT, Kohn AD, De Ferrari GV, Kaykas A. Wnt and β-catenin signaling: diseases and therapies. Nat Rev Genet 2004;5:691-701. (Pubitemid 39150127)
23. Van De Wetering M, Sancho E, Verweij C, de Lau W, Oving I, Hurlstone A, et al. The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell 2002;111:241-50. (Pubitemid 35292444)
24. Kolligs FT, Nieman MT, Winer I, Hu G, Van Mater D, Feng Y, et al. ITF-2, a downstream target of the Wnt/TCF pathway, is activated in human cancers with b-catenin defects and promotes neoplastic transformation. Cancer Cell 2002;1:145-55.
25. Chen B, Dodge ME, Tang W, Lu J, Ma Z, Fan CW, et al. Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Nat Chem Biol 2009;5:100-7.
26. Huang A, Mishina YM, Liu S, Cheung A, Stegmeier F, Michaud GA, et al. Tankyrase inhibition stabilizes axin and antagonizes Wnt signaling. Nature 2009;461:614-20.
27. Waaler J, Machon O, Tumova L, Dinh H, Korinek V, Wilson SR, et al. A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice. Cancer Res 2012;72:2822-32.
28. Semënov M, Tamai K, He X. SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. J Biol Chem 2005;29:26770-5.
29. Oloumi A, Syam S, Dedhar S. Modulation of Wnt3a-mediated nuclear beta-catenin accumulation and activation by integrin-linked kinase in mammalian cells. Oncogene 2006;25:7747-57. (Pubitemid 44967969)
30. Kumar R, Balasenthil S, Pakala SB, Rayala SK, Sahin AA, Ohshiro K. Metastasis-associated protein 1 short form stimulates Wnt1 pathway in mammary epithelial and cancer cells. Cancer Res 2010;70:6598-608.
31. Nakashima N, Huang CL, Liu D, Ueno M, Yokomise H. Intratumoral Wnt1 expression affects survivin gene expression in non-small cell lung cancer. Int J Oncol 2010;37:687-94.
32. Verras M, Brown J, Li X, Nusse R, Sun Z. Wnt3a growth factor induces androgen receptor-mediated transcription and enhances cell growth in human prostate cancer cells. Cancer Res 2004;64:8860-6. (Pubitemid 39665490)
33. Katoh M. Regulation of Wnt3 and Wnt3A mRNAs in human cancer cell lines NT2, MCF-7, and MKN45. Int J Oncol 2002;2:373-7.
34. Harland R, Gerhart J. Formation and function of Spermann's organizer. Annu Rev Cell Dev Biol 1997;13:611-67.
35. Zhu Y, Parada LF. The molecular and genetic basis of neurological tumours. Nat Rev Cancer 2002;2:616-26. (Pubitemid 37328928)
36. Holland EC. Glioblastoma multiforme: the terminator. Proc Natl Acad Sci 2000;97:6242-4. (Pubitemid 30412695)
37. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008;455:1061-8.
38. Zhang LY, Ye J, Zhang F, Li FF, Li H, Gu Y, et al. Axin induces cell death and reduces cell proliferation in astrocytoma by activating the p53 pathway. Int J Cancer 2009;35:25-32.
39. Kim MJ, Chia IV, Costantini F. SUMOylation target sites at the C terminus protect Axin from ubiquitination and confer protein stability. FASEB J 2008;22:3785-94.
40. Lui TT, Lacroix C, Ahmed SM, Goldenberg SJ, Leach CA, Daulat AM, et al. The Ubiquitin specific protease USP34 regulates Axin stability and Wnt/β-catenin signaling. Mol Cell Biol 2011;10:2053-65.
41. Kim S, Jho EH. The protein stability of Axin, a negative regulator of Wnt signaling, is regulated by Smad ubiquitination regulatory factor 2 (Smurf2). J Biol Chem 2010;285:36420-6.